Advanced search
Publication Cover
OncoImmunology Volume 9, 2020 - Issue 1
Submit an article Journal homepage
4,622
Views
36
CrossRef citations to date
0
Altmetric
Back Matter

Expression of TIM3/VISTA checkpoints and the CD68 macrophage-associated marker correlates with anti-PD1/PDL1 resistance: implications of immunogram heterogeneity

Shumei Katoa Center for Personalized Cancer Therapy and Division of Hematology and Oncology, Department of Medicine, UC San Diego Moores Cancer Center, La Jolla, CA, USACorrespondence[email protected]
View further author information
,
Ryosuke Okamuraa Center for Personalized Cancer Therapy and Division of Hematology and Oncology, Department of Medicine, UC San Diego Moores Cancer Center, La Jolla, CA, USAView further author information
,
Yuichi Kumakib Cancer Center, Tokyo Medical and Dental University, Tokyo, JapanView further author information
,
Sadakatsu Ikedab Cancer Center, Tokyo Medical and Dental University, Tokyo, JapanView further author information
,
Mina Nikanjama Center for Personalized Cancer Therapy and Division of Hematology and Oncology, Department of Medicine, UC San Diego Moores Cancer Center, La Jolla, CA, USAView further author information
,
Ramez Eskandera Center for Personalized Cancer Therapy and Division of Hematology and Oncology, Department of Medicine, UC San Diego Moores Cancer Center, La Jolla, CA, USAView further author information
,
Aaron Goodmana Center for Personalized Cancer Therapy and Division of Hematology and Oncology, Department of Medicine, UC San Diego Moores Cancer Center, La Jolla, CA, USAView further author information
,
Suzanna Leea Center for Personalized Cancer Therapy and Division of Hematology and Oncology, Department of Medicine, UC San Diego Moores Cancer Center, La Jolla, CA, USAView further author information
,
Sean T. Glennc OmniSeq Inc., Buffalo, NY, USA;d Center for Personalized Medicine, Roswell Park Cancer Institute, Buffalo, NY, USAView further author information
,
Devin Dressmanc OmniSeq Inc., Buffalo, NY, USAView further author information
,
Antonios Papanicolau-Sengosc OmniSeq Inc., Buffalo, NY, USAView further author information
,
Felicia L. Lenzoc OmniSeq Inc., Buffalo, NY, USAView further author information
,
Carl Morrisonc OmniSeq Inc., Buffalo, NY, USA;d Center for Personalized Medicine, Roswell Park Cancer Institute, Buffalo, NY, USAView further author information
&
Razelle Kurzrocka Center for Personalized Cancer Therapy and Division of Hematology and Oncology, Department of Medicine, UC San Diego Moores Cancer Center, La Jolla, CA, USAORCID Iconhttps://orcid.org/0000-0003-4110-1214View further author information
ORCID Icon show all
Article: 1708065 | Received 17 Jul 2019, Accepted 01 Nov 2019, Published online: 17 Feb 2020

Citations (36)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Ginette S. Santiago-Sánchez, Kellsye P. Fabian & James W. Hodge. (2024) A landscape of checkpoint blockade resistance in cancer: underlying mechanisms and current strategies to overcome resistance. Cancer Biology & Therapy 25:1.
Read now
Raquel S Laureano, Jenny Sprooten, Isaure Vanmeerbeerk, Daniel M Borras, Jannes Govaerts, Stefan Naulaerts, Zwi N Berneman, Benoit Beuselinck, Kalijn F Bol, Jannie Borst, an Coosemans, Angeliki Datsi, Jitka Fučíková, Lisa Kinget, Bart Neyns, Gerty Schreibelt, Evelien Smits, Rüdiger V Sorg, Radek Spisek, Kris Thielemans, Sandra Tuyaerts, Steven De Vleeschouwer, I Jolanda M de Vries, Yanling Xiao & Abhishek D Garg. (2022) Trial watch: Dendritic cell (DC)-based immunotherapy for cancer. OncoImmunology 11:1.
Read now

Articles from other publishers (34)

Jungah Lim, Razelle Kurzrock, Daisuke Nishizaki, Hirotaka Miyashita, Jacob J. Adashek, Suzanna Lee, Sarabjot Pabla, Mary Nesline, Jeffrey M. Conroy, Paul DePietro, Scott M. Lippman & Shumei Kato. (2023) Pan‐cancer analysis of TIM ‐3 transcriptomic expression reveals high levels in pancreatic cancer and interpatient heterogeneity . Cancer Medicine 13:1.
Crossref
Shawn Iadonato, Yulia Ovechkina, Kurt Lustig, Jessica Cross, Nathan Eyde, Emily Frazier, Neda Kabi, Chen Katz, Remington Lance, David Peckham, Shaarwari Sridhar, Carla Talbaux, Isabelle Tihista, Mei Xu & Thierry Guillaudeux. (2023) A highly potent anti-VISTA antibody KVA12123 - a new immune checkpoint inhibitor and a promising therapy against poorly immunogenic tumors. Frontiers in Immunology 14.
Crossref
Sena Zeynep Usta, Toshihiro Uchihashi, Shingo Kodama, Kyoko Kurioka, Toshihiro Inubushi, Takuya Shimooka, Akinari Sugauchi, Soju Seki & Susumu Tanaka. (2023) Current Status and Molecular Mechanisms of Resistance to Immunotherapy in Oral Malignant Melanoma. International Journal of Molecular Sciences 24:24, pages 17282.
Crossref
Shumei Kato, Sophia Gumas, Jacob J. Adashek, Ryosuke Okamura, Suzanna Lee, Jason K. Sicklick & Razelle Kurzrock. (2023) Multi‐omic analysis in carcinoma of unknown primary ( CUP ): therapeutic impact of knowing the unknown . Molecular Oncology.
Crossref
Jessica Jou, Shumei Kato, Hirotaka Miyashita, Kartheeswaran Thangathurai, Sarabjot Pabla, Paul DePietro, Mary K. Nesline, Jeffrey M. Conroy, Eitan Rubin, Ramez N. Eskander & Razelle Kurzrock. (2023) Cancer-Immunity Marker RNA Expression Levels across Gynecologic Cancers: Implications for Immunotherapy. Molecular Cancer Therapeutics 22:11, pages 1352-1362.
Crossref
Alberto Hernando-Calvo, Maria Vila-Casadesús, Yacine Bareche, Alberto Gonzalez-Medina, Farnoosh Abbas-Aghababazadeh, Deborah Lo Giacco, Agatha Martin, Omar Saavedra, Irene Brana, Maria Vieito, Roberta Fasani, John Stagg, Francesco Mancuso, Benjamin Haibe-Kains, Ming Han, Roger Berche, Trevor J. Pugh, Oriol Mirallas, Jose Jimenez, Nadia Saoudi Gonzalez, Claudia Valverde, Eva Muñoz-Couselo, Cristina Suarez, Marc Diez, Elena Élez, Jaume Capdevila, Ana Oaknin, Cristina Saura, Teresa Macarulla, Joan Carles Galceran, Enriqueta Felip, Rodrigo Dienstmann, Philippe L. Bedard, Paolo Nuciforo, Joan Seoane, Josep Tabernero, Elena Garralda & Ana Vivancos. (2023) A pan-cancer clinical platform to predict immunotherapy outcomes and prioritize immuno-oncology combinations in early-phase trials. Med 4:10, pages 710-727.e5.
Crossref
Hirotaka Miyashita, Razelle Kurzrock, Nicholas J. Bevins, Kartheeswaran Thangathurai, Suzanna Lee, Sarabjot Pabla, Mary Nesline, Sean T. Glenn, Jeffrey M. Conroy, Paul DePietro, Eitan Rubin, Jason K. Sicklick & Shumei Kato. (2023) T-cell priming transcriptomic markers: implications of immunome heterogeneity for precision immunotherapy. npj Genomic Medicine 8:1.
Crossref
Akram Mesleh Shayeb, Razelle Kurzrock, Jacob J. Adashek & Shumei Kato. (2023) Comprehensive Analysis of Human Epidermal Growth Factor Receptor 2 Through DNA, mRNA, and Protein in Diverse Malignancies. JCO Precision Oncology:7.
Crossref
Lara Heij, Jan Bednarsch, Xiuxiang Tan, Mika Rosin, Simone Appinger, Konrad Reichel, Dana Pecina, Michail Doukas, Ronald M. van Dam, Juan Garcia Vallejo, Florian Ulmer, Sven Lang, Tom Luedde, Flavio G. Rocha, Shivan Sivakumar & Ulf Peter Neumann. (2023) Expression of Checkpoint Molecules in the Tumor Microenvironment of Intrahepatic Cholangiocarcinoma: Implications for Immune Checkpoint Blockade Therapy. Cells 12:6, pages 851.
Crossref
Adam Wahida, Lars Buschhorn, Stefan Fröhling, Philipp J. Jost, Andreas Schneeweiss, Peter Lichter & Razelle Kurzrock. (2022) The coming decade in precision oncology: six riddles. Nature Reviews Cancer 23:1, pages 43-54.
Crossref
Nicholas J. Bevins, Ryosuke Okamura, Meagan Montesion, Jacob J. Adashek, Aaron M. Goodman & Razelle Kurzrock. (2022) Tumor Infiltrating Lymphocyte Expression of PD-1 Predicts Response to Anti-PD-1/PD-L1 Immunotherapy. Journal of Immunotherapy and Precision Oncology 5:4, pages 90-97.
Crossref
Yu Fujiwara, Shumei Kato, Mary K Nesline, Jeffrey M Conroy, Paul DePietro, Sarabjot Pabla & Razelle Kurzrock. (2022) Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy. Cancer Treatment Reviews 110, pages 102461.
Crossref
Yujing Li, Guannan Su, Fanfan Huang, Ying Zhu, Xiang Luo, Aize Kijlstra & Peizeng Yang. (2022) Identification of differently expressed mRNAs by peripheral blood mononuclear cells in Vogt-Koyanagi-Harada disease. Genes & Diseases 9:5, pages 1378-1388.
Crossref
Cheng Zhang, Xiaoyi Chong, Fangli Jiang, Jing Gao, Yang Chen, Keren Jia, Meng Fan, Xuan Liu, Jin An, Jian Li, Xiaotian Zhang & Lin Shen. (2022) Plasma extracellular vesicle derived protein profile predicting and monitoring immunotherapeutic outcomes of gastric cancer. Journal of Extracellular Vesicles 11:4.
Crossref
Jin Liu, Mingwei Gao, Zhou Yang, Yidan Zhao, Kun Guo, Binwen Sun, Zhenming Gao & Liming Wang. (2022) Macrophages and Metabolic Reprograming in the Tumor Microenvironment. Frontiers in Oncology 12.
Crossref
Fabien Thoreau & Vijay Chudasama. (2022) Enabling the next steps in cancer immunotherapy: from antibody-based bispecifics to multispecifics, with an evolving role for bioconjugation chemistry. RSC Chemical Biology 3:2, pages 140-169.
Crossref
Augusto Bleve, Francesca Maria Consonni, Chiara Porta, Valentina Garlatti & Antonio Sica. (2022) Evolution and Targeting of Myeloid Suppressor Cells in Cancer: A Translational Perspective. Cancers 14:3, pages 510.
Crossref
Anirban Das, Sumedha Sudhaman, Daniel Morgenstern, Ailish Coblentz, Jiil Chung, Simone C. Stone, Noor Alsafwani, Zhihui Amy Liu, Ola Abu Al Karsaneh, Shirin Soleimani, Hagay Ladany, David Chen, Matthew Zatzman, Vanja Cabric, Liana Nobre, Vanessa Bianchi, Melissa Edwards, Lauren C, Sambira Nahum, Ayse B. Ercan, Arash Nabbi, Shlomi Constantini, Rina Dvir, Michal Yalon-Oren, Gadi Abebe Campino, Shani Caspi, Valerie Larouche, Alyssa Reddy, Michael Osborn, Gary Mason, Scott Lindhorst, Annika Bronsema, Vanan Magimairajan, Enrico Opocher, Rebecca Loret De Mola, Magnus Sabel, Charlotta Frojd, David Sumerauer, David Samuel, Kristina Cole, Stefano Chiaravalli, Maura Massimino, Patrick Tomboc, David S. Ziegler, Ben George, An Van Damme, Nobuko Hijiya, David Gass, Rose B. McGee, Oz Mordechai, Daniel C. Bowers, Theodore W. Laetsch, Alexander Lossos, Deborah T. Blumenthal, Tomasz Sarosiek, Lee Yi Yen, Jeffrey Knipstein, Anne Bendel, Lindsey M. Hoffman, Sandra Luna-Fineman, Stefanie Zimmermann, Isabelle Scheers, Kim E. Nichols, Michal Zapotocky, Jordan R. Hansford, John M. Maris, Peter Dirks, Michael D. Taylor, Abhaya V. Kulkarni, Manohar Shroff, Derek S. Tsang, Anita Villani, Wei Xu, Melyssa Aronson, Carol Durno, Adam Shlien, David Malkin, Gad Getz, Yosef E. Maruvka, Pamela S. Ohashi, Cynthia Hawkins, Trevor J. Pugh, Eric Bouffet & Uri Tabori. (2022) Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency. Nature Medicine 28:1, pages 125-135.
Crossref
Jooeun Bae, Fabrizio Accardi, Teru Hideshima, Yu-Tzu Tai, Rao Prabhala, Aaron Shambley, Kenneth Wen, Sean Rowell, Paul G. Richardson, Nikhil C. Munshi & Kenneth C. Anderson. (2021) Targeting LAG3/GAL-3 to overcome immunosuppression and enhance anti-tumor immune responses in multiple myeloma. Leukemia 36:1, pages 138-154.
Crossref
Lixia Xia, Yinghui Yu, Fen Lan, Junrong Yan, Jinfan Li, Wen Li & Yang Xia. (2021) Case Report: Tumor Microenvironment Characteristics in a Patient With HER2 Mutant Lung Squamous Cell Carcinoma Harboring High PD-L1 Expression Who Presented Hyperprogressive Disease. Frontiers in Oncology 11.
Crossref
Songbo Zhao, Chunhua Wang, Ping Lu, Yalin Lou, Huimin Liu, Ting Wang, Shanshan Yang, Ziyou Bao, Lin Han, Xiaohong Liang, Chunhong Ma & Lifen Gao. (2021) Switch receptor T3/28 improves long-term persistence and antitumor efficacy of CAR-T cells. Journal for ImmunoTherapy of Cancer 9:12, pages e003176.
Crossref
Elena Fountzilas, Razelle Kurzrock, Henry Hiep Vo & Apostolia-Maria Tsimberidou. (2021) Wedding of Molecular Alterations and Immune Checkpoint Blockade: Genomics as a Matchmaker. JNCI: Journal of the National Cancer Institute 113:12, pages 1634-1647.
Crossref
Michelle N. Ferreira & Jennifer H. Choe. (2021) Guiding immunotherapy combinations: Who gets what?. Advanced Drug Delivery Reviews 178, pages 113962.
Crossref
R. Zou, Y. Wang, F. Ye, X. Zhang, M. Wang & S. Cui. (2021) Mechanisms of primary and acquired resistance to PD-1/PD-L1 blockade and the emerging role of gut microbiome. Clinical and Translational Oncology 23:11, pages 2237-2252.
Crossref
Khiyam Hussain, Mark S. Cragg & Stephen A. Beers. (2021) Remodeling the Tumor Myeloid Landscape to Enhance Antitumor Antibody Immunotherapies. Cancers 13:19, pages 4904.
Crossref
Martin Thelen, Kerstin Wennhold, Jonas Lehmann, Maria Garcia-Marquez, Sebastian Klein, Elena Kochen, Philipp Lohneis, Axel Lechner, Svenja Wagener-Ryczek, Patrick Sven Plum, Oscar Velazquez Camacho, David Pfister, Fabian Dörr, Matthias Heldwein, Khosro Hekmat, Dirk Beutner, Jens Peter Klussmann, Fabinshy Thangarajah, Dominik Ratiu, Wolfram Malter, Sabine Merkelbach-Bruse, Christiane Josephine Bruns, Alexander Quaas, Michael von Bergwelt-Baildon & Hans A. Schlößer. (2021) Cancer-specific immune evasion and substantial heterogeneity within cancer types provide evidence for personalized immunotherapy. npj Precision Oncology 5:1.
Crossref
Priyakshi Croft, Haarika Chittoory, Tam Nguyen, Jodi Saunus, Woo Kim, Amy E. McCart Reed, Malcolm Lim, Xavier De Luca, Kaltin Ferguson, Colleen Niland, Roberta Mazzieri, Riccardo Dolcetti, Peter Simpson & Sunil Lakhani. (2021) Characterization of Immune Cell Subsets of Tumor Infiltrating Lymphocytes in Brain Metastases. Biology 10:5, pages 425.
Crossref
Ji-Eun Irene Yum & Young-Kwon Hong. (2021) Terminating Cancer by Blocking VISTA as a Novel Immunotherapy: Hasta la vista, baby. Frontiers in Oncology 11.
Crossref
Alberto Mantovani, Federica Marchesi, Sebastien Jaillon, Cecilia Garlanda & Paola Allavena. (2021) Tumor-associated myeloid cells: diversity and therapeutic targeting. Cellular & Molecular Immunology 18:3, pages 566-578.
Crossref
Denis L. Jardim, Aaron Goodman, Debora de Melo Gagliato & Razelle Kurzrock. (2021) The Challenges of Tumor Mutational Burden as an Immunotherapy Biomarker. Cancer Cell 39:2, pages 154-173.
Crossref
Claudia Ceci, Maria Grazia Atzori, Pedro Miguel Lacal & Grazia Graziani. (2020) Targeting Tumor-Associated Macrophages to Increase the Efficacy of Immune Checkpoint Inhibitors: A Glimpse into Novel Therapeutic Approaches for Metastatic Melanoma. Cancers 12:11, pages 3401.
Crossref
Huan-Zhen Yang & Xi-Han Zhou. (2020) Mechanism for hypoxia inducible factor-1α to promote immune escape and therapeutic tolerance in hepatocellular carcinoma under hypoxic microenvironment. World Chinese Journal of Digestology 28:18, pages 904-913.
Crossref
Jacob J. Adashek, Yadis Arroyo-Martinez, Arjun K. Menta, Razelle Kurzrock & Shumei Kato. (2020) Therapeutic Implications of Epidermal Growth Factor Receptor (EGFR) in the Treatment of Metastatic Gastric/GEJ Cancer. Frontiers in Oncology 10.
Crossref
Michele Dal Bo, Elena De Mattia, Lorena Baboci, Silvia Mezzalira, Erika Cecchin, Yehuda G. Assaraf & Giuseppe Toffoli. (2020) New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma. Drug Resistance Updates 51, pages 100702.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.